FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

26 results

adstiladrin
(nadofaragene firadenovec-vncg)
Ferring Pharmaceuticals
Usage: ADSTILADRIN® is indicated for treating high-risk BCG-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) in adults, specifically for those with carcinoma in situ (CIS) with or without papillary tumors.
balversa
(Erdafitinib)
Janssen Products LP
Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.
eligard
(Leuprolide Acetate)
TOLMAR Inc.
Usage: ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.
erleada
(Apalutamide)
Janssen Products, LP
Usage: ERLEADA is indicated for treating metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).
fetroja
(Cefiderocol sulfate tosylate)
Shionogi Inc.
Usage: FETROJA® is indicated for patients aged 18 and older for treating complicated urinary tract infections (cUTIs) including pyelonephritis, and hospital-acquired/ventilator-associated bacterial pneumonia, caused by susceptible Gram-negative bacteria like E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Use should limit drug resistance.
firmagon
(Degarelix)
Ferring Pharmaceuticals Inc.
Usage: FIRMAGON® is indicated for the treatment of patients with advanced prostate cancer.
gemtesa
(vibegron)
Sumitomo Pharma America, Inc.
Usage: GEMTESA® is indicated for the treatment of overactive bladder (OAB) in adults, characterized by urge urinary incontinence, urgency, and urinary frequency. It is also indicated for adult males with OAB symptoms who are undergoing pharmacological therapy for benign prostatic hyperplasia (BPH).
injectafer
(Ferric Carboxymaltose Injection)
American Regent, Inc.
Usage: Injectafer is indicated for treating iron deficiency anemia in patients aged 1 year and older with oral iron intolerance or unsatisfactory response, and in non-dialysis dependent chronic kidney disease. It also treats iron deficiency in adults with heart failure (NYHA class II/III) to improve exercise capacity.
invokamet
(canagliflozin and metformin hydrochloride)
Janssen Pharmaceuticals, Inc.
Usage: INVOKAMET and INVOKAMET XR are indicated as adjuncts to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus. Canagliflozin component reduces risks of major cardiovascular events and kidney disease in specific patient populations.
invokana
(canagliflozin)
Janssen Pharmaceuticals, Inc.
Usage: INVOKANA (canagliflozin) is indicated as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients with type 2 diabetes. It reduces risks of major cardiovascular events and end-stage kidney disease in adults with type 2 diabetes and specific health complications. Usage in type 1 diabetes or severe renal impairment is not recommended.

Nephrology & Urology drugs

adstiladrin

balversa

eligard

erleada

fetroja

firmagon

gemtesa

injectafer

invokamet

invokana